Management of rheumatological conditions

The goal of immunomodulatory therapy is sustained remission with the aim of relieving pain and stiffness, improving ability to move, and preventing damage to joints.^2-6

Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of pharmacological treatment. They act to control the inflammation and therefore reduce symptoms and prevent joint damage. ^2xz-6

Upadacitinib provides a targeted synthetic DMARD option that can be considered when treating patients with moderate to severe RA, moderate to severe PsA or active AS.⁷

Guild Learning and development is pleased to announce the release of an education module on this topic titled ‘Rinvoq® (upadacitinib) for the management of rheumatological conditions’.

This module updates pharmacists on the symptoms, prevalence and treatment guidelines of certain rheumatological conditions including the impact on quality of life and the mental health of people who have the condition. The module looks at the best practice management of these conditions, with a focus on the use of Rinvoq^® (upadacitinib).

Guild Learning and Development thanks AbbVie for the provision of an educational grant which made this course possible. AbbVie is the manufacturer of Rinvoq® (upadacitinib).  Note: AbbVie had the opportunity to review information related to Rinvoq® (upadacitinib) for inaccuracies and omissions only.

To enrol in this course please visit guilded.guild.org.au

Please contact Guild Learning and Development on 1800 049 056 or email learninganddevelopment@guild.org.au for more information.

This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credits), suitable for inclusion in an individual pharmacist's CPD plan, which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.